Repligen Corporation — 2013 Form 10-K Summary
Business context and reporting period
Repligen develops and sells bioprocessing products, including Protein A, cell-culture growth factors, chromatography columns and test kits. The company reports one segment, with manufacturing operations in Waltham, Massachusetts, and Lund, Sweden. This filing covers the fiscal year ended December 31, 2013; quarterly data are unaudited. The prior-year comparison is the full year ended December 31, 2012.
Key financial metrics
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $68.17 million | $62.27 million |
| Bioprocessing product revenue | $47.48 million | $41.83 million |
| Royalty and other revenue | $20.69 million | $20.43 million |
| Operating income | $22.87 million | $11.08 million |
| Net income | $16.09 million | $14.16 million |
| Diluted EPS | $0.50 | $0.45 |
| Gross margin | 53% | 40% |
| Cash from operations | $25.93 million | $13.44 million |
At December 31, 2013, cash and marketable securities totaled $73.84 million, working capital was $75.05 million, and total assets were $118.64 million. Current liabilities were $11.30 million and other long-term liabilities were $3.46 million; the filing does not identify material borrowings. Cash and marketable securities increased from $49.97 million a year earlier. Investing activities used $17.91 million, including $13.27 million of net purchases of marketable securities and $4.63 million of capital expenditures. Management said existing cash was adequate for at least 24 months absent acquisitions.
Material changes versus the prior year
- Revenue rose 9%, led by 14% growth in bioprocessing product sales, principally from growth factors, affinity ligands and OPUS products.
- Operating income more than doubled as product costs fell 10%, manufacturing efficiencies improved and research and development expense declined 30% to $7.34 million. SG&A decreased 4% to $12.70 million.
- Net income increased 14%, despite a $6.92 million income tax provision in 2013 versus a $2.88 million tax benefit in 2012. The 2012 benefit included a $3.02 million valuation-allowance reversal.
- Orencia royalties from Bristol-Myers Squibb were $17.88 million in 2013, or 27% of revenue, but the royalty agreement expired on December 31, 2013. Repligen expects the loss to materially and adversely affect revenue and operating results.
- Revenue concentration remains significant: the largest bioprocessing customer accounted for 35% of 2013 revenue, while two other bioprocessing customers represented 12% and 13%.
Outlook, commentary and risks
- Management expected 2014 gross margin to remain relatively consistent with 2013, R&D expense to decrease slightly, SG&A to increase as customer-facing activities expand, and capital expenditures to decline.
- Repligen received $5 million upfront and a $1 million milestone from Pfizer for the SMA program, with up to $64 million in potential future milestones plus royalties. Pfizer controls further development and may terminate the agreement for convenience.
- In January 2014, Repligen licensed its HDAC inhibitor portfolio to BioMarin, receiving $2 million upfront with up to $160 million in potential milestones and royalties. These future payments depend on BioMarin’s development and commercialization efforts.
- RG1068 (SecreFlo) had received an FDA complete response letter requiring additional clinical efficacy and safety data. The company expected further development to depend on sponsors or other third parties.
- Risks include the loss of Orencia royalties, customer and product concentration, competition and pricing pressure, manufacturing and quality interruptions, foreign-exchange exposure, and dependence on partners for contingent licensing revenue. The company reported that 32% of 2013 revenue and 37% of costs and expenses were denominated in foreign currencies and did not hedge this exposure.
- A Massachusetts tax audit raised disputed issues involving historical research credits and allocation of intellectual-property settlement proceeds. Repligen recorded an $800,000 provision for the research-credit matter; it recorded no provision for the settlement-allocation matter, which it disputes. The filing also reports $1.675 million of unrecognized tax benefits and $238,000 of accrued interest and penalties.
- Operating lease obligations totaled $14.12 million; total disclosed fixed obligations, including purchase commitments and contingent consideration, were $18.06 million. No material legal proceedings were identified. Management and the auditor reported effective internal control over financial reporting, and the auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- How much bioprocessing revenue and operating profit can replace the expired Orencia royalties, and whether product growth can sustain margins.
- Whether customer concentration has changed and whether long-term supply agreements remain in force on disclosed terms.
- Progress, termination rights, milestones and royalty conditions under the Pfizer and BioMarin arrangements; potential payments are not assured.
- Outcome and potential exposure from the Massachusetts tax audit, including the unprovided-for settlement-allocation dispute.
- Whether cash generation, planned commercial investment and the stated liquidity runway remain adequate, particularly if the company pursues acquisitions.